HBV polymerase (reverse transcriptase) drugs for Chronic Hepatitis B

6 tracked HBV polymerase (reverse transcriptase) drugs in the Chronic Hepatitis B race. The class explanation lives on the HBV polymerase (reverse transcriptase) page; the full indication pipeline across every mechanism is on the Chronic Hepatitis B page.

3 approved / phase 42 Phase 31 preclinical / unstaged

Head-to-head evidence: Besifovir dipivoxil (Besivo) vs Entecavir (Baraclude) · Besifovir dipivoxil (Besivo) vs Entecavir (Cavir) · Besifovir dipivoxil (Besivo) vs Tenofovir amibufenamide (Hengmu) · Besifovir dipivoxil (Besivo) vs lamivudine (Epivir-HBV) · Besifovir dipivoxil (Besivo) vs tenofovir alafenamide (Vemlidy) · Entecavir (Baraclude) vs tenofovir alafenamide (Vemlidy)

The roster

← all HBV polymerase (reverse transcriptase) drugs